Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine

BACKGROUND: Lasmiditan (LTN) is a selective 5-HT(1F) receptor agonist for the acute treatment of migraine in adults. We present detailed safety findings from the placebo-controlled, double-blind Phase 3 study, of LTN treatment across 4 attacks (CENTURION). METHODS: Patients were randomized 1:1:1 to...

Descripción completa

Detalles Bibliográficos
Autores principales: Tassorelli, C, Bragg, S, Krege, JH, Doty, EG, Ardayfio, PA, Ruff, D, Dowsett, SA, Schwedt, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572440/
https://www.ncbi.nlm.nih.gov/pubmed/34742230
http://dx.doi.org/10.1186/s10194-021-01343-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572440/
https://www.ncbi.nlm.nih.gov/pubmed/34742230
http://dx.doi.org/10.1186/s10194-021-01343-2

Ejemplares similares